H.R. 5160 · 119th Congress

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Introduced on Sep 4, 2025 by Christopher H. Smith (R-NJ-4). 21 cosponsors, 11 of them from another party. Latest action (Jul 21, 2026): Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

Stage
Passed one chamber
Introduced
Sep 4, 2025
Cosponsors
21
11 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. Reported by committee
  3. Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

Subjects

  • Biological and life sciences
  • Blood and blood diseases
  • Cell biology and embryology
  • Health programs administration and funding
  • Organ and tissue donation and transplantation

Summary

By the Congressional Research Service (Reported to House, Jul 2, 2026). Public domain.

Stem Cell Therapeutic and Research Reauthorization Act of 2025

This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).

The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research.

Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

Christopher H. SmithR-NJ-4Sponsor

Democrats · 11

Republicans · 10

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Sep 4, 2025Introduced in House
  2. Sep 4, 2025Introduced in House
  3. Sep 4, 2025 · HouseReferred to the House Committee on Energy and Commerce.
  4. Sep 4, 2025 · HouseReferred to the Subcommittee on Health.
  5. May 13, 2026 · HouseSubcommittee Consideration and Mark-up Session Held
  6. May 13, 2026 · HouseForwarded by Subcommittee to Full Committee by Voice Vote.
  7. May 21, 2026 · HouseCommittee Consideration and Mark-up Session Held
  8. May 21, 2026 · HouseOrdered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
  9. Jul 2, 2026Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
  10. Jul 2, 2026 · HouseReported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
  11. Jul 2, 2026 · HousePlaced on the Union Calendar, Calendar No. 629.
  12. Jul 20, 2026 · HouseMr. Guthrie moved to suspend the rules and pass the bill, as amended.
  13. Jul 20, 2026 · HouseConsidered under suspension of the rules. (consideration: CR H4642-4643)
  14. Jul 20, 2026 · HouseDEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
  15. Jul 20, 2026Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
  16. Jul 20, 2026 · HouseOn motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
  17. Jul 20, 2026 · HouseMotion to reconsider laid on the table Agreed to without objection.
  18. Jul 21, 2026 · SenateReceived in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. NATIONAL MARROW DONOR PROGRAM4 reports
    $1.2M reported (all issues)Federal contractor: NATIONAL MARROW DONOR PROGRAM$27.8M in contracts, FY2026AI match · 100%
  2. Duke University Medical Center2 reports
    $20K reported (all issues)
  3. AMERICAN BENEFITS COUNCIL1 report
    $280K reported (all issues)
  4. American Association of Blood Banks, dba Association for the Advancement of Bloo1 report
    Federal contractor: AMERICAN ASSOCIATION OF BLOOD BANKS, INC.$706.2K in contracts, FY2026AI match · 100%
  5. New York Blood Center Enterprises1 report
    $90K reported (all issues)Federal contractor: NEW YORK BLOOD CENTER, INC$1.8M in contracts, FY2026AI match · 98%
  6. The Nemours Foundation - a Florida not-for-profit Corporation1 report
    $150K reported (all issues)

Reports filed in 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.